日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Type I Interferon Pathway Activation Disrupts Monocyte Maturation and Enhances Immune Evasion in Multiple Myeloma.

I型干扰素通路激活会破坏单核细胞成熟并增强多发性骨髓瘤的免疫逃逸。

期刊:Advanced Science
影响因子:14.1
doi:10.1002/advs.202510816
Cui Jian, Wang Jingwei, Li Xiaoyun, Wang Lina, Mao Xuehan, Lyv Rui, Yan Wenqiang, Xu Jingyu, Zhou Jieqiong, Du Chenxing, Deng Shuhui, Hao Mu, Xu Yan, Yi Shuhua, Zou Dehui, Cheng Tao, Gao Xin, Qiu Lugui, An Gang
多发性骨髓瘤
信号转导
单核细胞
骨髓瘤
细胞生物学
免疫/内分泌
发表日期：2026
文献求助 收藏

Talquetamab, a GPRC5D×CD3 bispecific antibody, in Chinese patients with relapsed/refractory multiple myeloma: efficacy and safety from the phase 1/2 MonumenTAL-1 study

Talquetamab（一种GPRC5D×CD3双特异性抗体）治疗中国复发/难治性多发性骨髓瘤患者的疗效和安全性：来自MonumentTAL-1 1/2期研究

期刊:Haematologica
影响因子:7.9
doi:10.3324/haematol.2025.287334
An, Gang; Jin, Jie; Cai, Zhen; Jing, Hongmei; Fu, Chengcheng; He, Pengcheng; Xia, Zhongjun; Liu, Rui; Li, Liang; Gai, Xue; Zhang, Hong; Zhu, Dian; Luo, Xinchao; Sun, Binbin; Xu, Hongmei; Zhou, Longen; Campagna, Michela; Masterson, Tara J; Lau, Bonnie W; Renaud, Thomas; Heuck, Christoph; Singh, Indrajeet; Vishwamitra, Deeksha; Qiu, Lugui
多发性骨髓瘤
CD3
骨髓瘤
发表日期：2026
文献求助 收藏

Real-world outcomes of isatuximab with pomalidomide and dexamethasone for relapsed and/or refractory multiple myeloma

伊沙妥昔单抗联合泊马度胺和地塞米松治疗复发和/或难治性多发性骨髓瘤的真实世界疗效

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003649
Chen, Wenting; You, Jianhua; Lin, Li'e; Yan, Xiaojing; An, Gang; Wang, Yafei; Tian, Weiwei; Ding, Kaiyang; Zhang, Xi; Chen, Wenming; Wang, Yingxue; Fang, Baijun; Liu, Jing; Xia, Weilin; Feng, Zhaoyi; Zhou, Lei; Wang, Zhini; Shen, Dan; Liu, Gang; Zhao, Weili
多发性骨髓瘤
骨髓瘤
发表日期：2026
文献求助 收藏

Recommendations for the diagnosis of extramedullary multiple myeloma

髓外多发性骨髓瘤诊断建议

期刊:Chinese Medical Journal
影响因子:7.3
doi:10.1097/CM9.0000000000003850
Shen, Kaini; Sun, Chunyan; Fu, Weijun; Zou, Dehui; Gao, Wen; An, Gang; Wang, Luqun; Li, Jian
多发性骨髓瘤
骨髓瘤
发表日期：2026
文献求助 收藏

Thalidomide-based regimen shows promising efficacy in large granular lymphocytic leukemia: a multicenter phase II study

一项多中心 II 期研究显示，基于沙利度胺的治疗方案在治疗大颗粒淋巴细胞白血病方面显示出良好的疗效。

期刊:Signal Transduction and Targeted Therapy
影响因子:52.7
doi:10.1038/s41392-025-02164-4
Yu, Ying; Li, Yuxi; Cui, Rui; Yan, Yuting; Li, Fei; Chen, Yan; Wang, Tingyu; Hu, Xiaoli; Feng, Yaqing; Yu, Tengteng; Huang, Yanshan; Sun, Jingwen; Lyu, Rui; Xiong, Wenjie; Wang, Qi; Liu, Wei; An, Gang; Sui, Weiwei; Xu, Yan; Huang, Wenyang; Zou, Dehui; Wang, Huijun; Xiao, Zhijian; Wang, Jianxiang; Qiu, Lugui; Yi, Shuhua
白血病
细胞生物学
发表日期：2025
文献求助 收藏

Chimeric antigen receptor with novel intracellular modules improves antitumor performance of T cells

具有新型胞内模块的嵌合抗原受体可提高T细胞的抗肿瘤活性

期刊:Signal Transduction and Targeted Therapy
影响因子:40.8
doi:10.1038/s41392-024-02096-5
Pengju Wang # ，Yiyi Wang # ，Xiaojuan Zhao # ，Rui Zheng ，Yiting Zhang ，Ruotong Meng ，Hao Dong ，Sixin Liang ，Xinyi He ，Yang Song ，Haichuan Su ，Bo Yan ，An-Gang Yang ，Lintao Jia
T细胞
免疫/内分泌
细胞生物学
肿瘤
信号转导
T细胞
肿瘤免疫
发表日期：2025
文献求助 收藏

Development and validation of a prognostic staging system for primary plasma cell leukemia.

原发性浆细胞白血病预后分期系统的建立与验证

期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-025-01723-0
Tian Mengru, An Gang, Fu Weijun, Yan Wenqiang, Li Lu, Sun Chunyan, Li Zhenyu, Chen Lijuan, Liao Aijun, Gao Guangxun, Qin Xiaoqi, Li Mengyao, Li Chunrui, Xue Hua, Gao Li, Wang Yi, He Aili, Zhou Fan, Guo Dongmei, Dong Yujun, Fang Zhihong, Chu Xiaoxia, Mi Jianqing, Fu Chengcheng, Zeng Hui, Hou Shuling, Wang Xiaotao, Wang Hua, Wei Yongqiang, Liang Xinyue, Yi Xingcheng, Sun Yue, Qiu Lugui, Dai Yun, Jin Fengyan
细胞生物学
发表日期：2025
文献求助 收藏

A novel indirubin- 3-monoxime derivative I3MV- 8b exhibits remarkable cytotoxicity against multiple myeloma by targeting TRIM28.

一种新型的靛玉红-3-单肟衍生物I3MV-8b通过靶向TRIM28对多发性骨髓瘤表现出显著的细胞毒性

期刊:Biomarker Research
影响因子:11.5
doi:10.1186/s40364-025-00773-3
Fang Teng, Liu Lanting, Sun Hao, Zhang Xiaoyu, Sun Xiyue, Yu Zhen, Gong Lixin, Xie Shiyi, Zhao Yonglong, Li Yan, Qiu Lugui, An Gang, He Bin, Hao Mu
细胞生物学
骨髓瘤
发表日期：2025
文献求助 收藏

Ibrutinib alternating with three cycles of interval fludarabine, cyclophosphamide, and rituximab (FCR) in adults with untreated chronic lymphocytic leukaemia as time-limited regimen: a single-arm, multicentre phase 2 trial in China

伊布替尼与三个周期的氟达拉滨、环磷酰胺和利妥昔单抗（FCR）方案交替用于未经治疗的成人慢性淋巴细胞白血病，作为限时治疗方案：一项在中国开展的单臂、多中心II期临床试验

期刊:EClinicalMedicine
影响因子:10
doi:10.1016/j.eclinm.2025.103688
Wang, Tingyu; Yan, Yuting; Wang, Hui; Sun, Ying; Liu, Xiantao; Lyu, Rui; Xiong, Wenjie; An, Gang; Liu, Wei; Xu, Yan; Deng, Shuhui; Wang, Qi; Du, Chenxing; Huang, Liang; Zou, Dehui; Zhao, Yaozhong; Qiu, Lugui; Li, Zengjun; Yi, Shuhua
白血病
细胞生物学
发表日期：2025
文献求助 收藏

Continuous R-DA-EDOCH alternated with high-dose Ara-C induces deep remission and overcomes high-risk factors in young patients with newly diagnosed mantle cell lymphoma

对于新诊断的年轻套细胞淋巴瘤患者，连续R-DA-EDOCH方案与高剂量Ara-C方案交替使用可诱导深度缓解并克服高危因素。

期刊:Cancer Biology & Medicine
影响因子:8.4
doi:10.20892/j.issn.2095-3941.2024.0200
Wang, Yi; Yan, Yuting; Shan, Dandan; Chen, Jiawen; Liu, Wei; Wang, Tingyu; An, Gang; Sui, Weiwei; Huang, Wenyang; Xiong, Wenjie; Liu, Huimin; Sun, Qi; Wang, Huijun; Xiao, Zhijian; Wang, Jianxiang; Qiu, Lugui; Zou, Dehui; Yi, Shuhua
细胞生物学
淋巴瘤
发表日期：2025
文献求助 收藏